Metformin use is associated with lower plasma NfL, higher CSF Aβ42 and better cognitive performance

Background Metformin use has been associated with a lower risk of dementia among people with diabetes through mechanisms potentially unrelated to glycaemic control. We investigated whether Alzheimer’s disease-related biomarkers may partly explain these associations. Methods We included 2443 participants with diabetes from the National Alzheimer’s Coordinating Center (NACC) and 1074 participants with endocrine/metabolic disorders from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Cognitive endpoints were the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), mini-mental state examination (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB). We compared metformin users and non-users with respect to cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels (ADNI: 38 vs 207; NACC: 45 vs 29) and plasma neurofilament light chain (NfL) levels (ADNI only: 36 vs 165). We performed adjusted linear regression models with robust variance estimation and exploratory mediation analyses interpreted as indirect statistical associations. Results In NACC, compared with non-users, metformin users (n=1285) had lower CDR-SB scores (regression coefficient (RC)=−0.73; 95% CI −1.07 to −0.38; p<0.001), higher MMSE scores (RC=0.70; 95% CI 0.01 to 1.39; p=0.048) and higher Aβ42 levels (RC=136.9; 95% CI 5.17 to 268.56; p=0.042). An indirect association through Aβ42 was observed for CDR-SB. In ADNI, metformin users (n=115) had lower ADAS-Cog scores (RC=−2.84; 95% CI −5.57 to −0.11; p=0.041) and lower plasma NfL levels (RC=−15.42; 95% CI −27.01 to −3.82; p=0.009). Indirect associations through NfL were observed for ADAS-Cog and CDR-SB. Conclusions Metformin use is associated with better cognitive outcomes, lower plasma NfL and higher cerebrospinal fluid (CSF) Aβ42 in individuals with diabetes and other metabolic conditions. These biomarkers represent candidate biological correlates of metformin-associated neuroprotection.

Authors

Institutions

Publication Details

Journal
Journal of Neurology Neurosurgery & Psychiatry
Published
2026-11-13
DOI
https://doi.org/10.1136/jnnp-2026-339219
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Metformin use is associated with lower plasma NfL, higher CSF Aβ42 and better cognitive performance

Stefano Del Prato, Jesus Thomas Abanto, Alberto Javier Espay, Camillo Imbimbo et al.
Journal of Neurology Neurosurgery & Psychiatry
Dementia and Cognitive Impairment Research
article

Metformin use is associated with lower plasma NfL, higher CSF Aβ42 and better cognitive performance

Stefano Del Prato, Jesus Thomas Abanto, Alberto Javier Espay, Camillo Imbimbo, Bruno Pietro Imbimbo, Alok K. Dwivedi
article en

Abstract

Background Metformin use has been associated with a lower risk of dementia among people with diabetes through mechanisms potentially unrelated to glycaemic control. We investigated whether Alzheimer’s disease-related biomarkers may partly explain these associations. Methods We included 2443 participants with diabetes from the National Alzheimer’s Coordinating Center (NACC) and 1074 participants with endocrine/metabolic disorders from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Cognitive endpoints were the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), mini-mental state examination (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB). We compared metformin users and non-users with respect to cerebrospinal fluid (CSF) amyloid-β42 (Aβ42) levels (ADNI: 38 vs 207; NACC: 45 vs 29) and plasma neurofilament light chain (NfL) levels (ADNI only: 36 vs 165). We performed adjusted linear regression models with robust variance estimation and exploratory mediation analyses interpreted as indirect statistical associations. Results In NACC, compared with non-users, metformin users (n=1285) had lower CDR-SB scores (regression coefficient (RC)=−0.73; 95% CI −1.07 to −0.38; p<0.001), higher MMSE scores (RC=0.70; 95% CI 0.01 to 1.39; p=0.048) and higher Aβ42 levels (RC=136.9; 95% CI 5.17 to 268.56; p=0.042). An indirect association through Aβ42 was observed for CDR-SB. In ADNI, metformin users (n=115) had lower ADAS-Cog scores (RC=−2.84; 95% CI −5.57 to −0.11; p=0.041) and lower plasma NfL levels (RC=−15.42; 95% CI −27.01 to −3.82; p=0.009). Indirect associations through NfL were observed for ADAS-Cog and CDR-SB. Conclusions Metformin use is associated with better cognitive outcomes, lower plasma NfL and higher cerebrospinal fluid (CSF) Aβ42 in individuals with diabetes and other metabolic conditions. These biomarkers represent candidate biological correlates of metformin-associated neuroprotection.

Journal of Neurology Neurosurgery & Psychiatry
Scuola Superiore Sant'Anna (IT), University of Pavia (IT), Chiesi (Italy) (IT), University of Cincinnati (US), University of Missouri (US)
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon